Form 4: NEOGENOMICS COO Stone Reports Equity Changes
Insider Ownership Change
NeoGenomics President & COO Warren Stone reported the vesting of restricted stock units and subsequent tax-related share disposition, alongside details of his extensive derivative holdings.
Summary
- Warren Stone, President & Chief Operating Officer of NeoGenomics Inc. (NEO), reported changes in his beneficial ownership of common stock.
- On January 13, 2026, Stone acquired 59,382 shares of common stock through the vesting of restricted stock units.
- Concurrently, 15,127 shares were disposed of to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, Stone beneficially owns 143,759 shares of common stock directly.
- The filing also details Stone's derivative holdings, including various stock options, performance stock units, and restricted stock units with different grant dates and vesting schedules.
Sentiment
Score: 6
Explanation: The filing reports routine insider equity transactions, including RSU vesting and tax-related share disposition. While the vesting is positive for the executive, the overall impact on the company's outlook is neutral as these are standard compensation events. The disclosure of extensive derivative holdings provides transparency into executive incentives.
Positives
- Vesting of 59,382 restricted stock units, converting into common stock, increasing direct ownership.
- Mr. Stone's promotion to President & Chief Operating Officer on April 1, 2025, led to modified vesting schedules for some equity grants, potentially accelerating his ownership.
Negatives
- Disposition of 15,127 shares of common stock to cover tax withholding obligations.
Future Outlook
The filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider ownership changes.
Industry Context
This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies. It reflects the standard practice of executive compensation through equity grants and subsequent vesting, which aligns management incentives with shareholder interests. It does not provide specific industry-related insights beyond the company's compensation practices.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President & Chief Operating Officer | NA | Warren Stone | 2025-04-01 | Promotion, which also led to modified vesting schedules for certain equity grants. |
Stakeholder Impact
- Shareholders: Provides transparency into executive compensation and ownership, aligning executive interests with company performance through equity grants.
- Employees: Reflects the company's executive compensation structure, which may influence broader compensation strategies.
Next Steps
- The filing does not specify any future actions or milestones for the company, focusing solely on the reported insider transactions.
Key Dates
| Date | Description |
|---|---|
| 2022-12-01 | Grant of 166,113 stock options to Mr. Stone, vesting ratably over four years. |
| 2023-05-11 | Grant of 53,969 stock options to Mr. Stone, vesting ratably over three years. |
| 2023-05-11 | Grant of 21,204 performance stock units to Mr. Stone, vesting based on target performance. |
| 2023-05-11 | Grant of 28,838 restricted stock units to Mr. Stone, vesting ratably over three years. |
| 2024-02-23 | Grant of 42,344 stock options to Mr. Stone, vesting ratably over three years. |
| 2024-02-23 | Grant of 25,329 restricted stock units to Mr. Stone, vesting ratably over three years. |
| 2024-02-23 | Grant of 25,330 performance stock units to Mr. Stone, vesting based on share and revenue growth goals. |
| 2024-05-02 | Grant of 29,976 stock options to Mr. Stone, vesting ratably over three years. |
| 2024-05-02 | Grant of 17,905 restricted stock units to Mr. Stone, vesting ratably over three years. |
| 2024-05-02 | Grant of 17,908 performance stock units to Mr. Stone, vesting based on share and revenue growth goals. |
| 2025-02-21 | Grant of 143,266 premium-price stock options to Mr. Stone, initially vesting ratably over three years. |
| 2025-02-21 | Grant of 84,317 restricted stock units to Mr. Stone, initially vesting ratably over three years. |
| 2025-04-01 | Mr. Stone's promotion to President & Chief Operating Officer, leading to modified vesting schedules for certain equity grants. |
| 2025-04-01 | Grant of 94,518 premium-price stock options to Mr. Stone, vesting ratably over 12, 18, and 24 months. |
| 2025-04-01 | Grant of 52,687 restricted stock units to Mr. Stone, vesting ratably over 12, 18, and 24 months. |
| 2026-01-13 | Transaction date for RSU vesting and tax withholding. |
| 2026-01-15 | Signature date of the filing. |
| 2026-05-11 | Expiration date for 21,204 performance stock units. |
| 2027-02-23 | Expiration date for 25,330 performance stock units. |
| 2027-05-02 | Expiration date for 17,908 performance stock units. |
| 2029-12-01 | Expiration date for 166,113 stock options. |
| 2030-05-11 | Expiration date for 53,969 stock options. |
| 2034-02-23 | Expiration date for 42,344 stock options. |
| 2034-05-02 | Expiration date for 29,976 stock options. |
| 2035-02-21 | Expiration date for 143,266 stock options. |
| 2035-04-01 | Expiration date for 94,518 stock options. |
Recommendation
holdThis Form 4 details routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and subsequent tax withholding. While it provides transparency into executive ownership and incentives, it does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. These are expected events under an existing compensation plan.
Keywords
NeoGenomics, NEO, Warren Stone, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.